Abstract
Aims
Spontaneous osteonecrosis of the knee (SONK) mainly affects the medial femoral condyle, would be a good indication for UKA. The primary aim of this study was to assess the clinical, functional and radiographic outcomes at middle to long-term follow-up, of a consecutive series of fifty UKA used for the treatment of SONK. The secondary aim was to assess the volume of necrotic bone and determine if this influenced the outcome.
Patients and Methods
We reviewed 50 knees who were treated for SONK. Patients included ten males and 38 females. The mean age was 73 years (range, 57 to 83 years). The mean height and body weight were, respectively 153 cm (141 ∼171 cm) and 57 kg (35 ∼75kg). All had been operated on using the Oxford mobile-bearing UKA (Zimmer-Biomet, Swindon, United Kingdom) with cement fixation. The mean follow-up period was 8.4 years (range, 4 to 15years). We measured the size (width, length and depth) and the volume to be estimated (width x length x depth) of the necrotic bone mass using MRI in T1-weighted images.
The clinical results were evaluated using the Knee Society Scoring System (KSS) and Oxford Knee Score (OKS). The flexion angle of the knee was evaluated using lateral X-ray images in maximum flexion.
Results
There were no implant failures, but there were 4 deaths (from causes unrelated to UKA) mean 6.6 years after surgery(5∼8), 3 cases were lost mean 3.3 years after surgery(2∼5). The mean size of the necrotic lesion were 17.2mm (14.7∼25.3) in width, 28.2mm (6.2∼38.3) in length and 11.3mm (3.2∼14.3) in depth. The mean volume of it was calculated to be approximate 5.4 cm3 (0.7∼11.1). The mean flexion of the knee, KSS Knee Score, Function Score and OKS increased from a preoperative 128.7 degrees (110 ∼ 140 degrees) to 137.5 degrees (110 ∼ 153 degrees), 52.3 (30 ∼ 64) to 91.3 (87 ∼ 100), 39.7 (15∼ 55) to 90.2 (65 ∼ 100) and 21.6 (12∼ 28) to 40.2 (34∼ 48), respectively at the latest follow-up. At last follow-up all patients had good or excellent OKS.
Conclusions
There was a 100% survival rate of the Oxford Phase 3 UKA for SONK in the middle to long-term (up to 15 years after surgery) in this independent study. All patients had good/excellent results at last follow-up and there were no reoperations or major complications. This suggests that Oxford mobile-bearing UKA is a good and definitive treatment for medial femoral SONK, whatever the size of the lesion.
